Invesco BLDRS Developed Markets 100 ADR Index Fund
Most Recent
Analysts’ Estimates and Ratings for Novartis in October
Novartis’s revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
GlaxoSmithKline Stock’s June Performance
British multinational pharmaceutical company GlaxoSmithKline (GSK) divides its business into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
GW Pharmaceuticals: Recommendations and Market Capitalization
Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.
GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
Five analysts are currently tracking GlaxoSmithKline ADR. One analyst recommends a “strong buy,” and four analysts recommend a “hold.”
GlaxoSmithKline’s Revenue Was Flat in Second Quarter
GlaxoSmithKline (GSK) reported revenues of 7.3 billion pounds during the second quarter of 2018.
GlaxoSmithKline’s Q2 2018 Earnings: Analysts’ Estimates
Analysts are estimating that GlaxoSmithKline’s (GSK) revenues will decrease 1.5% to 7.2 billion pounds in Q2 2018.
Novartis Reports Growth in Q2 2018 Earnings
Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.
Sanofi’s Established Prescription Products in 4Q17
Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16.
Ablynx Acquisition Strengthens SNY’s Rare Blood Disorder Platform
Ablynx currently has more than 45 proprietary and partnered programs for the development of new treatments in the therapeutic areas of hematology, inflammation, respiratory disease, oncology, and immuno-oncology.
Sanofi’s $11.6 Billion Bioverativ Acquisition: Highlights
On January 22, 2018, Sanofi announced that it had entered into an agreement with Bioverativ to acquire all of its outstanding shares for $105 per share in cash.
GSK Has Emerged as Leading Player in Over-the-Counter Market
GlaxoSmithKline (GSK) is currently the leader in the 135 billion pound consumer healthcare market.
GSK Is Focused on Innovative Assets in Oncology Research Pipeline
In 2018, GlaxoSmithKline aims to initiate a pivotal phase 2 trial to evaluate GSK 916 as monotherapy Darzalex refractory population as the fourth line or the last line of multiple myeloma therapy.
AstraZeneca’s 4Q17 Estimates: Segment Revenues
AstraZeneca’s (AZN) cardiovascular and metabolics diseases segment’s revenues are expected to decrease in 4Q17 due to lower sales of Crestor and Byetta.
Novartis on the Street: Analyst Ratings and Recommendations
Novartis (NVS) reported revenues of ~$12.4 billion and EPS (earnings per share) of $1.29 for 3Q17, which represented a growth of 2% in revenues.
Teva Pharmaceutical Focusing on Per Product Operating Profits
Teva Pharmaceutical plans to increase the prices of certain products in its portfolio since the current prices are cited as unsustainable by the company.
Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018
In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type two diabetes mellitus.
Behind Sanofi’s Genzyme Business in 3Q17
Sanofi’s genzyme business reported revenues of 1.63 billion euros in 3Q17, representing a 12.5% YoY (year-over-year) rise in operating revenues.
How AstraZeneca’s Nexium, Synagis, and Losec Have Performed in 2017
In 3Q17, AstraZeneca’s (AZN) Nexium generated revenues of $469.0 million, which reflected an ~9.0% decline on a year-over-year basis.
AstraZeneca’s Anti-Diabetes Drugs Onglyza and Bydureon in 2017
In 3Q17, AstraZeneca’s (AZN) Onglyza generated revenues of $127.0 million, which reflected an ~25.0% decline on a year-over-year basis
AstraZeneca’s Performance by Segment in 3Q17
The CVMD segment reported a 4% fall in revenues at constant exchange rates to ~$1.8 billion during 3Q17.
What GlaxoSmithKline’s 3Q17 Performance Tells Us
GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.
Vaccines Business Expected to Boost Sanofi’s Revenues in 2017
In 2Q17, Sanofi’s (SNY) vaccine business reported revenues of 1.0 billion euros, which is a YoY rise of 26.2% on a CER basis and 19.2% on a CER and CS basis.
A Look at Novo Nordisk’s Hemophilia Franchise after 2Q17
In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.
How Does Novartis’s Ophthalmology Portfolio Look?
In 1H17, Novartis’s (NVS) Travoprost drugs reported revenues of around $290 million, which is a ~6% decline on a YoY basis.
Why New Generic Products Could Boost TEVA’s Revenue Growth
In August 2017, Teva Pharmaceutical (TEVA) launched the generic version of Eli Lilly’s (LLY) Axiron.
Analyzing GlaxoSmithKline’s Global Pharmaceuticals Business
GlaxoSmithKline’s (GSK) global pharmaceuticals business is a part of the pharmaceuticals segment. It reported revenues of 3.24 billion pounds during 2Q17.
GSK’s 2Q17 Earnings: Consumer Healthcare
GlaxoSmithKline (GSK) reported flat international revenues at constant exchange rates to 843.0 million pounds during 2Q17.
AstraZeneca Expects Brilinta to Become a Blockbuster Therapy in 2017
In 1Q17, AstraZeneca’s (AZN) Brilinta reported total revenues of ~$224 million, which is 27% growth year-over-year on a constant currency basis.
Sanofi Pasteur: Why Human Vaccines Matter
Sanofi Pasteur, Sanofi’s human vaccines business, reported a 3.7% sequential rise in revenues at constant exchange rates in 4Q16.
AstraZeneca’s Faslodex Expected to Benefit from FALCON Trial Data
On March 2, 2016, combination therapy Faslodex and palbociclib was approved by the FDA for HR+ human epidermal growth factor receptor 2 negative (or HER2) metastatic breast cancer.
